IMG_E1413

コメント

  • コメント (10)

  • トラックバックは利用できません。

  1. Emergence of resistance while on therapy necessitates repeat culture and susceptibility.

  2. Can be used in some pediatric fungal infections with appropriate weight-based dosing.

  3. The development of rezafungin highlights the ongoing search for agents with fluconazole’s convenience but broader activity.

  4. Emergence of resistance while on therapy necessitates repeat culture and susceptibility.

  5. Diflucan is ineffective against Lomentospora prolificans.

  6. Acquired resistance often involves upregulation of efflux pumps or target site mutations.

  7. A test dose can sometimes be used to assess for hypersensitivity in patients with prior reactions.

  8. Diflucan is not first-line for invasive aspergillosis under any circumstances.

  9. Diflucan achieves high concentrations in vaginal tissue, explaining its efficacy.

  10. A post-antimicrobial effect has been demonstrated against some Candida species.